3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Phase 2
1
Status
Recruiting
1
Completed
1
Sponsor Class
OTHER
64
NIH
25
NETWORK
16
INDUSTRY
2
Study Type
Observational
5
Interventional
2
Sponsor
Cancer Type
Other neoplasm
1
Gynecologic
1
Genitourinary
1
Conditions
Uterine Neoplasms
1
Uterine Diseases
1
Uterine Cervical Neoplasms
1
Uterine Cervical Dysplasia
1
Uterine Cervical Diseases
1
Urogenital Neoplasms
1
Urogenital Diseases
1
Prostatic Neoplasms
1
Precancerous Conditions
1
Neoplasms by Site
1
Neoplasms
1
Genital Neoplasms, Female
1
Genital Diseases, Female
1
Genital Diseases
1
Female Urogenital Diseases and Pregnancy Complications
1
Interventions
pembrolizumab
1019
Carboplatin
959
Paclitaxel
932
Gemcitabine
793
Cisplatin
748
Docetaxel
682
Bevacizumab
610
Pemetrexed
502
Nivolumab
486
Cyclophosphamide
466
Capecitabine
461
Fluorouracil
417
Dexamethasone
402
Rituximab
372
Oxaliplatin
347
Injections
342
atezolizumab
297
Trastuzumab
297
Leucovorin
286
Cetuximab
282
Irinotecan
266
130-nm albumin-bound paclitaxel
252
Prednisone
244
Doxorubicin
240
Ipilimumab
226
Lenalidomide
220
Fulvestrant
217
fludarabine
214
durvalumab
205
Erlotinib Hydrochloride
188
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
INDUSTRY
×
Interventional
×
Watchful Waiting
×
Clear all
NCT06815939
2026-01-29
OPTICS
DL Analytics
Phase NA
Recruiting
10,000 enrolled
NCT02799745
2024-12-06
ENACT
Astellas Pharma Inc
Phase 2
Completed
227 enrolled
24 charts